Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Cost-Cutting Program Will Help Beat First Quarter Expectations, Company Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck expects first quarter performance will come in at 62¢ per share, about 11% ahead of analysts' expectations. Despite stronger-than-expected first quarter, Merck is reaffirming full-year guidance.

You may also be interested in...



Prevnar, Effexor, Enbrel Powering Strong First Quarter For Wyeth

Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.

After Vioxx Withdrawal, First Thing For Merck Is Paying The Lawyers

Merck increases reserve for legal defense costs related to Vioxx by $604 mil., bringing the total to $675 mil.; the company has not yet established a reserve to cover potential liability. A hearing to consolidate pretrial motions to a single federal judge is scheduled for Jan. 27.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Topics

UsernamePublicRestriction

Register

PS061981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel